Download PDF
Thromb Haemost 2013; 109(01): 3-4
DOI: 10.1160/TH12-11-0835
Invited Editorial Focus
Schattauer GmbH

Perioperative anticoagulation in device implantation: Benefitting the uninterrupted

Roderick Tung
1   UCLA Health System, David Geffen School of Medicine at UCLA, UCLA Medical Center, Los Angeles, California, USA
,
Noel G. Boyle
1   UCLA Health System, David Geffen School of Medicine at UCLA, UCLA Medical Center, Los Angeles, California, USA
› Author Affiliations
Further Information

Publication History

Received: 19 November 2012

Accepted: 19 November 2012

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

Editorial Focus on: Feng et al. Thromb Haemost 2012; 108: 1124–1131.

 

  • References

  • 1 Wysokinski WE, McBane 2nd RD. Periprocedural bridging management of anticoagulation. Circulation 2012; 126: 486-490. DOI:10.1161/CIRCULATIONAHA.112.092833.
    CrossrefPubMedGoogle Scholar
  • 2 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the european heart rhythm association [EHRA], endorsed by the european society of cardiology [ESC] working group on thrombosis. Thromb Haemost 2011; 106: 997-1011. DOI:10.1160/TH11-10-0690.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Chen S, Liu J, Pan W. et al. Thromboembolic events during the perioperative period in patients undergoing permanent pacemaker implantation. Clin Cardiol 2012; 35: 83-87. DOI:10.1002/clc.21955.
    CrossrefPubMedGoogle Scholar
  • 4 Douketis JD. Contra: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery”. Thromb Haemost 2012; 108: 210-212. DOI:10.1160/TH12-04-0236.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Spyropoulos AC. Pro: “Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery”. Thromb Haemost 2012; 108: 213-216. DOI:10.1160/TH12-04-0217.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Feng L, Li Y, Li J. et al. Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices. A meta-analysis. Thromb Haemost 2012; 108: 1124-1131. DOI:10.1160/TH12-07-0498.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60. DOI:10.1160/TH09-05-0327.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Ahrens I, Lip GY, Peter K. What do the re-ly, averroes and rocket-af trials tell us for stroke prevention in atrial fibrillation?. Thromb Haemost 2011; 105: 574-578. DOI:10.1160/TH10-12-0808.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Pengo V, Crippa L, Falanga A. et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the italian federation of thrombosis centers (FCSA). Thromb Haemost 2011; 106: 868-876. DOI:10.1160/TH11-05-0358.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127. DOI:10.1160/TH09-11-0758.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847. DOI:10.1160/TH11-10-0718.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Omran H, Bauersachs R, Rubenacker S. et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre bnk online bridging registry (border). Thromb Haemost 2012; 108: 65-73. DOI:10.1160/TH11-12-0827.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Siegal D, Yudin J, Kaatz S. et al. Periprocedural heparin bridging in patients receiving vitamin k antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630-1639. DOI:10.1161/CIRCULATIONAHA.112.105221.
    CrossrefPubMedGoogle Scholar
  • 14 Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation 2012; 126: 1573-1576. DOI:10.1161/CIRCULATIONAHA.112.135681.
    CrossrefPubMedGoogle Scholar
  • 15 de Bono J, Nazir S, Ruparelia N. et al. Perioperative management of anticoagulation during device implantation-the uk perspective. Pacing Clin Electrophysiol 2010; 33: 389-393. DOI:10.1111/j.1540-8159.2009.02683.x.
    CrossrefPubMedGoogle Scholar
  • 16 Lip GY, Proclemer A, Dagres N. et al. Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation. Europace 2012; 14: 741-744. DOI:10.1093/europace/eus105.
    CrossrefPubMedGoogle Scholar
  • 17 Di Biase L, Burkhardt JD, Mohanty P. et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550-2556. DOI:10.1161/CIRCULATIONAHA.109.921320.
    CrossrefPubMedGoogle Scholar